Collegium to Present at the H.C. Wainwright Global Life Sciences Conference

CANTON, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 10, 2018 at 11:55 a.m. CET at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative, differentiated products for patients suffering from pain. 

About Xtampza ER

Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Contact:
Alex Dasalla
[email protected]

You May Also Be Interested In

• Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026
• H.C. Wainwright Reiterates Buy Rating on Oculis Holding AG (OCS)
• HBAR Price Prediction: Can Hedera Reclaim $0.10 as Remittix Earn Readies Morpho, Fluid and Maple Finance Pools?